Promising link between selenium and peroxisome proliferator activated receptor gamma in the treatment protocols of obesity as well as depression

Medical Hypotheses

Volumn 89, Issue , 2016, Pages 79-83

  Donma, M M ^a   Donma, O ^b  

^a NAMIK KEMAL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA PHENYL SELENOCITRONELLAL; ALPHA SELENOTOCOPHEROL; DIHYDROXYSELENOLANE; DIPHENYL DISELENIDE; FALCARINDIOL; HONOKIOL; METHYL PHENYL SELENIDE; METHYL SELENIDE; MONOAMINESELENOLANE; ORGANOSELENIUM DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SELENIUM; TRIPHENYL SELENONIUM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOGENESIS; ANTICARCINOGENIC ACTIVITY; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLADDER DISEASE; BONE DISEASE; CLINICAL PROTOCOL; CONFORMATIONAL TRANSITION; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; FLUID RETENTION; HEART FAILURE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; INSULIN RESISTANCE; LIGAND BINDING; LIVER TOXICITY; MINERAL SUPPLEMENTATION; MOLECULAR INTERACTION; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN FUNCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; WEIGHT GAIN; AGONISTS; BIOLOGICAL MODEL; EVIDENCE BASED MEDICINE; IMMUNOLOGY;

DEPRESSION; EVIDENCE-BASED MEDICINE; HUMANS; MODELS, IMMUNOLOGICAL; OBESITY; PPAR GAMMA; SELENIUM;

EID: 84960193391     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2016.02.008     Document Type: Article

References (84)

1. Kroker A.J., Bruning J.B. Review of the structural and dynamic mechanisms of PPARγ partial agonism. PPAR Res 2015, 2015:816856.
2. Savage D.B. PPAR gamma as a metabolic regulator: insights from genomics and pharmacology. Expert Rev Mol Med 2005, 7(1):1-16.
3. Shao X., Wang M., Wei X., et al. Peroxisome Proliferator-Activated Receptor-γ: master regulator of adipogenesis and obesity. Curr Stem Cell Res Ther 2015, [Epub ahead of print].
4. Jeffcoat R. Obesity - a perspective based on the biochemical interrelationship of lipids and carbohydrates. Med Hypotheses 2007, 68(5):1159-1171.
5. Farshbaf M.J., Ghaedi K., Shirani M., Nasr-Esfahani M.H. Peroxisome proliferator activated receptor gamma (PPARγ) as a therapeutic target for improvement of cognitive performance in Fragile-X. Med Hypotheses 2014, 82(3):291-294.
6. Nenov M.N., Laezza F., Haidacher S.J., et al. Cognitive enhancing treatment with a PPARγ agonist normalizes dentate granule cell presynaptic function in Tg2576 APP mice. J Neurosci 2014, 34(3):1028-1036.
7. Tontonoz P., Spiegelman B.M. Fat and beyond: the diverse biology of PPAR gamma. Annu Rev Biochem 2008, 77:289-312.
8. Choi S.S., Park J., Choi J.H. Revisiting PPARγ as a target for the treatment of metabolic disorders. BMB Rep 2014, 47(11):599-608.
9. Chigurupati S., Dhanaraj S.A., Balakumar P. A step ahead of PPARγ full agonists to PPARγ partial agonists: therapeutic perspectives in the management of diabetic insulin resistance. Eur J Pharmacol 2015, 755:50-57.
10. Chen L., Yang G. PPARs integrate the mammalian clock and energy metabolism. PPAR Res 2014, 2014:653017.
11. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004, 351(11):1106-1118.
12. Kapadia R., Yi J.H., Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 2008, 13:1813-1826.
13. Subramani P.A., Reddy M.C., Narala V.R. The need for physiologically relevant peroxisome proliferator-activated receptor-gamma (PPAR-γ) ligands. Endocr Metab Immune Disord Drug Targets 2013, 13(2):175-183.
14. Sumiyoshi M., Satomi J., Kitazato K.T., et al. PPARγ-dependent and -independent inhibition of the HMGB1/TLR9 pathway by eicosapentaenoic acid attenuates ischemic brain damage in ovariectomized rats. J Stroke Cerebrovasc Dis 2015, 24(6):1187-1195.
15. Luo H., Zhou Y., Hu X., et al. Activation of PPARγ2 by PPARγ1 through a functional PPRE in transdifferentiation of myoblasts to adipocytes induced by EPA. Cell Cycle 2015, 14(12):1830-1841.
16. Song C., Manku M.S., Horrobin D.F. Long-chain polyunsaturated fatty acids modulate interleukin-1beta-induced changes in behavior, monoaminergic neurotransmitters, and brain inflammation in rats. J Nutr 2008, 138(5):954-963.
17. Song C., Zhang X.Y., Manku M. Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment. J Neurosci 2009, 29(1):14-22.
18. Braeckman R.A., Manku M.S., Bays H.E., Stirtan W.G., Soni P.N. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study). Prostaglandins Leukot Essent Fatty Acids 2013, 89(4):195-201.
19. Błaz˙ewicz A., Klatka M., Astel A., et al. Serum and urinary selenium levels in obese children: a cross-sectional study. J Trace Elem Med Biol 2015, 29:116-122.
20. Młyniec K., Gaweł M., Doboszewska U., et al. Essential elements in depression and anxiety. Part II. Pharmacol Rep 2015, 67(2):187-194.
21. Cardoso B.R., Roberts B.R., Bush A.I., Hare D.J. Selenium, selenoproteins and neurodegenerative diseases. Metallomics 2015, 7(8):1213-1228.
22. Navarro-Alarcon M., Cabrera-Vique C. Selenium in food and the human body: a review. Sci Total Environ 2008, 400(1-3):115-141.
23. Pitts M.W., Byrns C.N., Ogawa-Wong A.N., Kremer P., Berry M.J. Selenoproteins in nervous system development and function. Biol Trace Elem Res 2014, 161(3):231-245.
24. Shahsavarian A., Javadi S., Jahanabadi S., et al. Antidepressant-like effect of atorvastatin in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway. Eur J Pharmacol 2014, 745:52-58.
25. Fidelak J., Ferrer S., Oberlin M., Moras D., Dejaegere A., Stote R.H. Dynamic correlation networks in human peroxisome proliferator-activated receptor-γ nuclear receptor protein. Eur Biophys J 2010, 39(11):1503-1512.
26. Korczak D.J., Pereira S., Koulajian K., Matejcek A., Giacca A. Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link. Diabetologia 2011, 54:2483-2493.
27. Li C.R., Mueller E.E., Bradley L.M. Islet antigen-specific Th17 cells can induce TNF-α-dependent autoimmune diabetes. J Immunol 2014, 192(4):1425-1432.
28. Zhao G., Dharmadhikari G., Maedler K., Meyer-Hermann M. Possible role of interleukin-1β in type 2 diabetes onset and implications for anti-inflammatory therapy strategies. PLoS Comput Biol 2014, 10(8):e1003798.
29. Maedler K., Sergeev P., Ehses J.A., et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci U S A 2004, 101:8138-8143.
30. Phillips A.C. Blunted cardiovascular reactivity relates to depression, obesity, and self-reported health. Biol Psychol 2011, 86(2):106-113.
31. Stice E., Spoor S., Bohon C., Small D.M. Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science 2008, 322:449-452.
32. Bylsma L.M., Morris B.H., Rottenberg J. A meta-analysis of emotional reactivity in major depressive disorder. Clin Psychol Rev 2008, 28:676-691.
33. McFarland B.R., Klein D.N. Emotional reactivity in depression: diminished responsiveness to anticipated reward but not to anticipated punishment or to nonreward or avoidance. Depress Anxiety 2009, 26:117-122.
34. Lovallo W.R., Farag N.H., Sorocco K.H., Cohoon A.J., Vincent A.S. Lifetime adversity leads to blunted stress axis reactivity: studies from the Oklahoma Family Health Patterns Project. Biol Psychiatry 2012, 71(4):344-349.
35. Downs C.A., Faulkner M.S. Toxic stress, inflammation and symptomatology of chronic complications in diabetes. World J Diabetes 2015, 6(4):554-565.
36. Marcovecchio M.L., Chiarelli F. The effects of acute and chronic stress on diabetes control. Sci Signal 2012, 5:pt10.
37. Tuck R.R., Schmelzer J.D., Low P.A. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 1984, 107(Pt 3):935-950.
38. Grafe P., Bostock H., Schneider U. The effects of hyperglycaemic hypoxia on rectification in rat dorsal root axons. J Physiol 1994, 480(Pt 2):297-307.
39. Silva N., Atlantis E., Ismail K. A review of the association between depression and insulin resistance: pitfalls of secondary analyses or a promising new approach to prevention of type 2 diabetes?. Curr Psychiatry Rep 2012, 14:8-14.
40. Champaneri S., Wand G.S., Malhotra S.S., Casagrande S.S., Golden S.H. Biological basis of depression in adults with diabetes. Curr Diab Rep 2010, 10:396-405.
41. Pereira S.S., Alvarez-Leite J.I. Low-grade inflammation, obesity, and diabetes. Curr Obes Rep 2014, 3(4):422-431.
42. Lasselin J., Capuron L. Chronic low-grade inflammation in metabolic disorders: relevance for behavioral symptoms. Neuroimmunomodulation 2014, 21:95-101.
43. Rayman M.P. The importance of selenium to human health. Lancet 2000, 356(9225):233-241.
44. Gandhi U.H., Kaushal N., Ravindra K.C., et al. Selenoprotein-dependent up-regulation of hematopoietic prostaglandin D2 synthase in macrophages is mediated through the activation of peroxisome proliferator-activated receptor (PPAR) gamma. J Biol Chem 2011, 286(31):27471-27482.
45. Lang U.E., Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem 2013, 31(6):761-777.
46. 2 stimulate glucose transporter mRNA expression and glucose uptake in primary human adipose stromal cells. J Interferon Cytokine Res 2015, 35(8):600-605.
47. Soczynska J.K., Kennedy S.H., Woldeyohannes H.O., et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromol Med 2011, 13(2):93-116.
48. Ortiz-Domínguez A., Hernández M.E., Berlanga C., et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord 2007, 9(6):596-602.
49. O'Brien S.M., Scully P., Scott L.V., Dinan T.G. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 2006, 90(2-3):263-267.
50. Brietzke E., Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(6):1355-1361.
51. Sirota P., Hadi E., Djaldetti M., Bessler H. Difference in inflammatory cytokine production by mononuclear cells from obese and non-obese schizophrenic patients. Acta Psychiatry Scand 2015, 132(4):301-305.
52. Dhanya B.L., Swathy R.P., Indira M. Selenium downregulates oxidative stress-induced activation of leukotriene pathway in experimental rats with diabetic cardiac hypertrophy. Biol Trace Elem Res 2014, 161(1):107-115.
53. Ying X., Chen X., Cheng S., et al. SeMet inhibits IL-1β-induced rheumatoid fibroblast-like synoviocytes proliferation and the production of inflammatory mediators. Biol Trace Elem Res 2013, 153(1-3):437-445.
54. Bruning C.A., Martini F., Soares S.M., Savegnago L., Sampaio T.B., Nogueira C.W. Depressive-like behavior induced by tumor necrosis factor-α is attenuated by m-trifluoromethyl-diphenyl diselenide in mice. J Psychiatry Res 2015, 66-67:75-83.
55. Li R., Xu X., Chen C., et al. CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the PPARγ. Am J Physiol Endocrinol Metab 2015, 308(4):E270-E282.
56. Zhang W., Zhang R., Wang T., et al. Selenium inhibits LPS-induced pro-inflammatory gene expression by modulating MAPK and NF-κβ signaling pathways in mouse mammary epithelial cells in primary culture. Inflammation 2014, 37(2):478-485.
57. Inestrosa N.C., Godoy J.A., Quintanilla R.A., Koenig C.S., Bronfman M. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp Cell Res 2005, 304(1):91-104.
58. Konarski J.Z., McIntyre R.S., Kennedy S.H., Rafi-Tari S., Soczynska J.K., Ketter T.A. Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord 2008, 10(1):1-37.
59. Aihara M., Ida I., Yuuki N., et al. HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions. Psychiatry Res 2007, 155(3):245-256.
60. Kariharan T., Nanayakkara G., Parameshwaran K., et al. Central activation of PPAR-gamma ameliorates diabetes induced cognitive dysfunction and improves BDNF expression. Neurobiol Aging 2015, 36(3):1451-1461.
61. Lang U.E., Beglinger C., Schweinfurth N., Walter M., Borgwardt S. Nutritional aspects of depression. Cell Physiol Biochem 2015, 37(3):1029-1043.
62. Verreth W., De Keyzer D., Pelat M., et al. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 2004, 110(20):3259-3269.
63. Heneka M.T., Landreth G.E., Hüll M. Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Nat Clin Pract Neurol 2007, 3(9):496-504.
64. Young-Xu Y., Chan K.A., Liao J.K., Ravid S., Blatt C.M. Long-term statin use and psychological well-being. J Am Coll Cardiol 2003, 42(4):690-697.
65. Derbeneva S.A., Bogdanov A.R., Pogozheva A.V., et al. Effect of diet enriched with selenium on the psycho-emotional and adaptive capacity of patients with cardiovascular diseases and obesity. Vopr Pitan 2012, 81(4):35-41.
66. Adriani M., Diarry V.I., Abdulah R., Wirjatmadi B. Selenium intake in hypertensive and normotensive post-menopausal Indonesian women. J Nutr Sci Vitaminol (Tokyo) 2015, 61(4):322-325.
67. Kim H.N., Song S.W. Concentrations of chromium, selenium, and copper in the hair of viscerally obese adults are associated with insulin resistance. Biol Trace Elem Res 2014, 158(2):152-157.
68. Conner T.S., Richardson A.C., Miller J.C. Optimal serum selenium concentrations are associated with lower depressive symptoms and negative mood among young adults. J Nutr 2015, 145(1):59-65.
69. Johnson L.A., Phillips J.A., Mauer C., et al. The impact of GPX1 on the association of groundwater selenium and depression: a Project FRONTIER study. BMC Psychiatry 2013, 13:7.
70. Gao S., Jin Y., Unverzagt F.W., et al. Selenium level and depressive symptoms in a rural elderly Chinese cohort. BMC Psychiatry 2012, 12:72.
71. Pasco J.A., Jacka F.N., Williams L.J., et al. Dietary selenium and major depression: a nested case-control study. Complement Ther Med 2012, 20(3):119-123.
72. Mokhber N., Namjoo M., Tara F., et al. Effect of supplementation with selenium on postpartum depression: a randomized double-blind placebo-controlled trial. J Matern Fetal Neonatal Med 2011, 24(1):104-108.
73. Chen L., Jia Z., Yang G. Editorial. PPARs and metabolic syndrome. PPAR Res 2014, 2014:832606.
74. Młyniec K. Zinc in the glutamatergic theory of depression. Curr Neuropharmacol 2015, 13(4):505-513.
75. Waku T., Shiraki T., Oyama T., Maebara K., Nakamori R., Morikawa K. The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites. EMBO J 2010, 29(19):3395-3407.
76. Atanasov A.G., Blunder M., Fakhrudin N., et al. Polyacetylenes from Notopterygium incisum-new selective partial agonists of peroxisome proliferator-activated receptor-gamma. PLoS One 2013, 8(4):e61755.
77. Atanasov A.G., Wang J.N., Gu S.P., et al. Honokiol: a non-adipogenic PPARγ agonist from nature. Biochim Biophys Acta 2013, 1830(10):4813-4819.
78. Li X., Xu B., Wang Y., Wei L. Anti-inflammatory effect of peroxisome proliferator activated receptor-γ (PPAR-γ) on non-obese diabetic mice with Sjögren's syndrome. Int J Clin Exp Pathol 2014, 7(8):4886-4894.
79. Desvergne B., Wahli W. Peroxisome proliferator activated receptors: nuclear control of metabolism. Endocr Rev 1999, 20(5):649-688.
80. Liu J., Rozovsky S. Membrane-bound selenoproteins. Antioxid Redox Signal 2015, 23(10):795-813.
81. Rosa R.M., Roesler R., Braga A.L., Saffi J., Henriques J.A. Pharmacology and toxicology of diphenyl diselenide in several biological models. Braz J Med Biol Res 2007, 40(10):1287-1304.
82. Ip C., Lisk D.J., Ganther H.E. Activities of structurally-related lipophilic selenium compounds as cancer chemopreventive agents. Anticancer Res 1998, 18(6A):4019-4025.
83. Kunwar A., Verma P., Priyadarsini K.I., Arai K., Iwaoka M. Comparative cytotoxicity and antioxidant evaluation of biologically active fatty acid conjugates of water soluble selenolanes in cells. Global advances in selenium research from theory to application 2015, 49-50. Taylor & F Francis Group, London. G.S. Banuelos, Z.Q. Lin, M.F. Moraes, L.R.G. Guilherme, A.R. das Reis (Eds.).
84. Victoria F.N., Anversa R., Penteado F., Castro M., Leonardao E.J., Savegnago L. Antioxidant and antidepressant-like activities of semisynthetic α-phenylselenocitronellal. Eur J Pharmacol 2014, 742:131-138.